Michael Centola

Michael Centola is the co-founder and CSO of PolySkope Labs. Michael is also the CEO and CSO of Haus Bioceuticals, Inc. Haus Bioceutical is a specialty pharmaceutical company that focuses on developing natural product-based drugs and dietary supplements. Their R&D team is comprised of experts in the fields of naturopathic and allopathic medicine, immunology, and inflammatory biology. They use state of the art laboratories for lead compound identification, mechanism of action studies, and preclinical assessments. In addition, they have an active clinical trial program to identify indications and to quantify efficacy and safety profiles relative to current standards of care. Clinically active bioceuticals are put through the same rigorous development process as pharmaceutical medicines, bridging the worlds of pharmacologic and naturopathic medicine. This is a unique approach, a third path, where the full potential and mechanisms of action of these natural safe and effective anti-inflammatory treatments is being understood and harnessed in an evidenced-based manner for the first time. Technologies appropriate for the OTC space are developed into proto-brands by crowdsourcing consumer’s requirements on the largest online commercial channel (Amazon.com) and social media advertising, which is further supported by bioceutical-specific regulatory strategies. Ultimately, technologies and proto-brands are licensed to leading channel partners in the consumer products and professional spaces. In addition to “in-haus” programs, Haus establishes co-development partnerships with other companies. Haus has completed preclinical and clinical development of their first technology and proto-brand, “MetaDerm”, a proprietary combination herbal-based treatment for chronic inflammatory skin diseases including eczema and psoriasis with unmatched efficacy and safety. Michael Centola has been with Haus Bioceuticals for 11 years and 5 months.